EliChip is a portable immunoassay platform, developed by Trustech Diagnostics, that converts your existing ELISA-type assay into a disposable microfluidic cartridge and benchtop reader. From a 20 µL sample, it delivers a quantitative digital result in under an hour, without a centralized laboratory or specialized personnel.
“ELISA-grade” means detection limits at the pg/mL level, matched or exceeded against a reference lab ELISA in independent testing (see published evidence).
For research and development use. Regulatory certification status varies by assay and market.
EliChip is a quantitative point-of-care immunoassay platform: the category of tests that bring laboratory-grade, numeric results to the field, the production line, or the point of care, instead of a qualitative yes/no read.
Talk to us about the Early Adopter Program, a strategic partnership, or investing in EliChip.
Standard ELISA delivers quantitative pg/mL-level results but needs a centralized lab, 100 to 200 µL of sample, and up to 24 hours. Lateral flow is fast but only qualitative. PCR and LAMP cannot detect proteins or toxins. EliChip is built to close that gap.
| Feature | Lateral flow | ELISA | PCR (molecular) | EliChip |
|---|---|---|---|---|
| Sensitivity (quantitative) | ||||
| Simplicity (ease of use) | ||||
| Matrix tolerance (robustness) | * | |||
| Portability (field use) | ||||
| Cost-effective hardware |
* PCR/LAMP amplification itself can run in a portable instrument. Matrix tolerance is the limiting factor: for most sample matrices, nucleic acid extraction and purification at the point of care still comes with a significant loss of sensitivity versus lab-based extraction. "Cost-effective hardware" reflects relative instrument capex, not a specific price commitment.
Analyte types and sample compatibility for EliChip reflect matrices and targets evaluated to date; feasibility for a new analyte or matrix is confirmed during the EAP assessment step. Multi-target multiplexing within a single card is on the roadmap, not a current capability.
EliChip uses microfluidic reagent handling and real-time, absorbance-based optical calibration to turn a raw sample directly into a quantitative result, without a separate lab step.
A 20 µL sample is loaded into the disposable microfluidic cartridge, pre-loaded with the assay-specific reagents.
The benchtop reader handles reagents and generates a real-time calibration curve for that specific run, without a centralized lab.
A numeric, ELISA-grade result is produced in under an hour and can be logged to a single database across locations.
EliChip has been used in feasibility and research work across agrifood, plant health, veterinary, and clinical and translational research.
EliChip is TRL-7 and has been tested in feasibility and research collaborations across these sectors. It is not currently a certified in vitro diagnostic (IVD) device; regulatory pathway and certification are assessed per assay and per market during the Early Adopter Program.
Two independent research collaborations show how EliChip performs against a laboratory ELISA reference, in agrifood and biomedical matrices.
Mycotoxins are toxic compounds naturally produced by fungi, typically found in cereals, dried fruit, nuts, and spices. They are difficult to detect: they are small molecules, toxic even at very low concentrations, colourless, tasteless, and not eliminated by heat treatment, filtration, or other food processing.
The chart compares EliChip measurements against a laboratory ELISA reference for Aflatoxin B1 concentration in corn extract. This case study was developed through Trustech Diagnostics' agrifood research collaborations, including the FDM digital agrifood platform project.
EliChip has been evaluated hands-on by clinical and academic groups outside Trustech, and cited in peer-reviewed literature.
EliChip is TRL-7 today as a single-analyte, quantitative point-of-care platform. Its multi-chemistry, multi-matrix cartridge architecture is being developed toward multiplexed and predictive use, alongside inflammation, oncology, and other application areas beyond the current portfolio.
A single quantitative, ELISA-grade result per cartridge run, TRL-7, in use across agrifood and biomedical research collaborations.
Multiple markers read from a single cartridge and sample, on the same microfluidic and reader architecture. Feasible on the current platform, in development and not yet a validated capability.
Multi-marker panels combined into a single digital, comparable readout across runs and sites, aimed at earlier and more predictive decisions rather than a single result in isolation.
Auralis Biotech is EliChip's strategic commercial partner, leading partner identification and market access across three tracks.
For assay owners: turn an existing ELISA-type test into a field-deployable EliChip cartridge, commercialized under your own brand, with scoped market exclusivity.
See how it works ↓For IVD manufacturers, distributors, and other companies already active in immunodiagnostics, agritech, or animal health, looking to integrate or distribute EliChip.
Talk about partnership →A TRL-7, IP-protected point-of-care platform with peer-reviewed evidence and traction across four sectors. See what we are building and where the round stands.
Talk to us about investing →Your existing validated assay, as the starting point
Limited, targeted adaptation to the cartridge format
Operational at or near the point of need
EliChip's development draws on Trustech Diagnostics' participation in EU and Italian-funded research programs, several of which apply the platform directly to biomarker detection.
Università del Piemonte Orientale
INEB · Instituto de Engenharia Biomédica, Porto
Agritest
NODES · Industria della Salute e Silver Economy
Horizon 2020
EnginSoft
TissueGraft
Riga Technical University
DiaSorin
Queen Mary University of London
Max Planck Institute
CNR NANOTEC
AO Research Institute Davos
Politecnico di Torino
AOU SS. Antonio e Biagio, AlessandriaInstitutions listed are research and clinical collaborators engaged through Trustech's funded projects and independent evaluations of EliChip.
Contact us to discuss feasibility for your assay, no commitment required.
EliChip is TRL-7, backed by peer-reviewed evidence, 3 patents (2 granted in Italy, 1 pending in the EU), and a growing Early Adopter Program. If you are evaluating an investment or a strategic partnership in point-of-care immunodiagnostics, we would like to talk.
Talk to us about investing